Results of SAVANNAH Global Phase II Trial at WCLC
Shares Magazine,
Press Release - 49% ORR amongst SAVANNAH patients with higher MET levels - Hong Kong, Shanghai & Florham Park, NJ - Wednesday…
Press Release - 49% ORR amongst SAVANNAH patients with higher MET levels - Hong Kong, Shanghai & Florham Park, NJ - Wednesday…
In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Na…
Please enter a search term. Please enter a search term. News provided by Jul 12, 2022, 8:00 PM ET HONG KONG and SHANGHAI, China…
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the…
— 49% ORR amongst SAVANNAH patients with higher MET levels — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) …
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Na…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) …
— 49% ORR amongst SAVANNAH patients with higher MET levels — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM…
— 49% ORR amongst SAVANNAH patients with higher MET levels — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12…
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 7, 2022: (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that…
Press Release Hong Kong, Shanghai & Florham Park, NJ - Monday, March 7, 2022: ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13…
GlobeNewswire 2022-03-07 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/A…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“”) (Nasdaq/AIM:HCM; HKEX:13) today…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“”) (Nasdaq/AIM:HCM; HKEX:13) today…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“”) (Nasdaq/AIM:HCM; HKEX:13) today…
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients…
Press Release - Follows important findings from the TATTON[1] study of the combination in EGFR inhibitor refractory lung cancer…
— Follows important findings from the TATTON 1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON 1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
GlobeNewswire 2021-11-24 — Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose…